Small-molecule MDM2-p53 inhibitors: Recent advances

Future Medicinal Chemistry

Volumn 7, Issue 5, 2015, Pages 631-645

  Zhang, Bian ^a   Golding, Bernard T ^a   Hardcastle, Ian R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IDASANUTLIN; NUTLIN; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; SMALL MOLECULE TRANSPORT AGENT; SPIROOXINDOLE; UNCLASSIFIED DRUG; 4 AMINOBENZOIC ACID DERIVATIVE; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; MOLECULAR LIBRARY; NUTLIN 2; OXINDOLE; PIPERAZINE DERIVATIVE; PYRROLIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; CLINICAL TRIAL (TOPIC); DIASTEREOISOMER; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SELECTIVITY; GENE AMPLIFICATION; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; REVIEW; STEREOCHEMISTRY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; TUMOR REGRESSION; X RAY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; NEOPLASMS; PHARMACOLOGY; THERAPEUTIC USE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMIDAZOLES; INDOLES; MODELS, MOLECULAR; NEOPLASMS; PARA-AMINOBENZOATES; PIPERAZINES; PROTEIN INTERACTION MAPS; PROTO-ONCOGENE PROTEINS C-MDM2; PYRROLIDINES; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84929997128     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.13     Document Type: Review

References (39)

1. Lane DP. Cancer. p53, guardian of the genome. Nature 358, 15-16 (1992).
2. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 4(10), 793-805 (2004).
3. Vousden KH, Lu X. Live or let die: the cells response to p53. Nat. Rev. Cancer 2, 594-604 (2002).
4. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-Associated protein in human sarcomas. Nature 358(6381), 80-83 (1992).
5. Oliner JD, Pietenpol JA, Thiagalingam S, Gvuris J, Kinzler KW, Vogelstein B. Oncoprotein mdm2 conceals the activation domain of tumor suppressor-p53. Nature 362(6423), 857-860 (1993).
6. Momand J, Zambetti GP, Olson DC, George D, Levine A. The mdm-2 oncogene product forms a complex with p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245 (1992).
7. Momand J, Wu H-H, Dasgupta G. MDM2 - master regulator of the p53 tumor suppressor protein. Gene 242(1-2), 15-29 (2000).
8. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6(12), 909-923 (2006).
9. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2; - fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9, 2523-2529 (1994).
10. Böttger V, Böttger A, Howard SF et al. Identification of novel mdm2 binding peptides by phage display. Oncogene 13(10), 2141-2147 (1996).
11. Garcia-Echeverria C, Chene P, Blommers MJJ, Furet P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem. 43(17), 3205-3208 (2000).
12. Kussie PH, Gorina S, Marechal V et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996).
13. Weber L. Patented inhibitors of p53-Mdm2 interaction (2006 -2008). Exp. Opin. Ther. Patents 20(2)179-191(2010).
14. Khoury K, Popowicz GM, Holak TA, Domling A. The p53-MDM2/MDMX axis - A chemotype perspective. Med Chem Comm 2(4), 246-260 (2011).
15. Zak K, Pecak A, Rys B et al. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 - present). Expert Opin. Ther. Patents 23(4)425- 448(2013).
16. Watson AF, Liu J, Bennaceur K et al. MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones. Bioorg. Med. Chem. Lett. 21(19), 5916- 5919 (2011).
17. Ray-Coquard I, Blay J-Y, Italiano A et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-Amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proofof- mechanism study. Lancet Oncol. 13(11), 1133-1140 (2012).
18. Vassilev LT, Vu BT, Graves B et al. In vivo Activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
19. Vu B, Wovkulich P, Pizzolato G et al. Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development. ACS Med. Chem. Lett. 4(5), 466-469 (2013).
20. Zaytsev A, Dodd B, Magnani M et al. Searching for dual inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interaction by a scaffold-hopping approach. Chem. Biol. Drug Des. doi:10.1111/cbdd.12474 (2014) (Epub ahead of print).
21. Miyazaki M, Kawato H, Naito H et al. Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein- protein interaction inhibitors: synthesis, biological evaluation and structure-Activity relationships. Bioorg. Med. Chem. Lett. 22(20), 6338-6342 (2012).
22. Miyazaki M, Naito H, Sugimoto Y et al. Lead optimization of novel p53-MDM2 interaction inhibitors possessing dihydroimidazothiazole scaffold. Bioorg. Med. Chem. Lett. 23(3), 728-732 (2013).
23. Yu S, Qin D, Shangary S et al. Potent and orally active smallmolecule inhibitors of the MDM2-p53 Interaction. J. Med. Chem. 52(24), 7970-7973 (2009).
24. Shangary S, Qin D, McEachern D et al. A novel orally active MDM2 inhibitor (MI-219) activates the p53 pathway and is selectively toxic to tumor cells. Mol. Cancer Ther. 6(12), S3518-S3518 (2007).
25. Zhao Y, Liu L, Sun W et al. Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J. Am. Chem. Soc. 135(19), 7223-7234 (2013).
26. Zhao Y, Yu S, Sun W et al. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J. Med. Chem. 56(13), 5553-5561 (2013).
27. Ding Q, Zhang Z, Liu J-J et al. Discovery of RG7388, a potent and selective p53-mdm2 inhibitor in clinical development. J. Med. Chem. 56(14), 5979-5983 (2013).
28. Zhang Z, Ding Q, Liu J-J et al. Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy. Bioorg. Med. Chem. 22(15), 4001-4009 (2014).
29. Zhang Z, Chu X-J, Liu J-J et al. Discovery of potent and orally active p53-MDM2 inhibitors RO5353 and RO2468 for potential clinical development. ACS Med. Chem. Lett. 5(2), 124-127 (2013).
30. Furet P, Chne P, De Pover A et al. The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction. Bioorg. Med. Chem. Lett. 22(10), 3498-3502 (2012).
31. Vaupel A, Bold G, De Pover A et al. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction. Bioorg. Med. Chem. Lett. 24(9), 2110-2114 (2014).
32. Ma Y, Lahue BR, Shipps Jr GW, Brookes J, Wang Y. Substituted piperidines as HDM2 inhibitors. Bioorg. Med. Chem. Lett. 24(4), 1026-1030 (2014).
33. Ma Y, Lahue BR, Gibeau CR et al. Pivotal role of an aliphatic side chain in the development of an HDM2 inhibitor. ACS Med. Chem. Lett. 5(5), 572-575 (2014).
34. Michelsen K, Jordan JB, Lewis J et al. Ordering of the N-terminus of human MDM2 by small molecule inhibitors. J. Am. Chem. Soc. 134(41), 17059-17067 (2012).
35. Rew Y, Sun D, Gonzalez-Lopez De Turiso F et al. Structurebased design of novel inhibitors of the MDM2-p53 interaction. J. Med. Chem. 55(11), 4936-4954 (2012).
36. Sun D, Li Z, Rew Y et al. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J. Med. Chem. 57(4), 1454-1472 (2014).
37. Gonzalez AZ, Li Z, Beck HP et al. Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres. J. Med. Chem. 57(7), 2963-2988 (2014).
38. Gonzalez-Lopez de Turiso F, Sun D, Rew Y et al. Rational design and binding mode duality of MDM2-p53 inhibitors. J. Med. Chem. 56(10), 4053-4070 (2013).
39. Gonzalez AZ, Eksterowicz J, Bartberger MD et al. Selective and potent morpholinone inhibitors of the MDM2- p53 protein-protein interaction. J. Med. Chem. 57(6), 2472-2488 (2014).